Next Article in Journal
IgE-Mediated Food Sensitization, Management Strategies, and Quality of Life in Pediatric Eosinophilic Esophagitis: A Prospective Observational Study
Previous Article in Journal
Integrating Traditional Nutritional Wisdom into Digital Nutrition Platforms: Toward Culturally Adaptive and Inclusive Health Technologies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 17
Issue 12
10.3390/nu17121979
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Association Between Low Omega-6 Polyunsaturated Fatty Acid Levels and the Development of Delirium in the Coronary Intensive Care Unit

by
Yurina Sugita-Yamaguchi
1,
Tetsuro Miyazaki
1,2,*,
Kazunori Shimada
1,
Megumi Shimizu
1,
Shohei Ouchi
1,
Tatsuro Aikawa
1,
Tomoyuki Shiozawa
1,
Kiyoshi Takasu
1,
Masaru Hiki
1,
Shuhei Takahashi
1,
Katsuhiko Sumiyoshi
3 and
Tohru Minamino
1
1
Department of Biology and Cardiovascular Medicine, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo 113-8421, Japan
2
Laboratory of Bioregulatory Clinical Pharmacology, Faculty of Pharmacy, Juntendo University, 6-8-1 Hinode, Urayasu 279-0013, Japan
3
Department of Health and Nutrition, Faculty of Human Sciences, Tokiwa University, 1-430-1 Miwa, Mito 310-5385, Japan
*
Author to whom correspondence should be addressed.
Nutrients 2025, 17(12), 1979; https://doi.org/10.3390/nu17121979
Submission received: 17 May 2025 / Revised: 2 June 2025 / Accepted: 7 June 2025 / Published: 11 June 2025
(This article belongs to the Section Clinical Nutrition)
Browse Figures
Review Reports Versions Notes

Abstract

:
Background: Delirium is frequently observed in patients admitted to the intensive care unit, and is associated with mortality and morbidity. Although several studies have reported an association between polyunsaturated fatty acids (PUFAs) and cognitive disorders, the association between PUFA levels and development of delirium in patients with acute cardiovascular disease remains unknown. Objective: This study aimed to clarify the association between PUFA levels and development of delirium in the coronary intensive care unit (CICU). Methods: We enrolled 590 consecutive patients (mean age, 70 ± 14 years) admitted to the CICU of Juntendo University Hospital. Fasting serum PUFA levels were measured within 24 h of admission. Delta-5 desaturase activity was estimated as the ratio of arachidonic acid (AA) to dihomo-gamma-linolenic acid (DGLA). Furthermore, delirium was defined as patients having a delirium score of ≥4 using the Intensive Care Delirium Screening Checklist. Results: Delirium was observed in 55 patients. DGLA levels were significantly lower, and delta-5 desaturase activity was significantly higher in patients with delirium than in those without delirium (both p < 0.001). Conversely, AA alone and omega-3 PUFAs did not differ between the groups. Additionally, DGLA and AA levels, but not omega-3 PUFA levels, were negatively associated; delta-5 desaturase activity was positively associated with the delirium score (both p < 0.001). The duration of delirium was significantly associated with DGLA and AA levels (p = 0.001 and p = 0.004, respectively). Moreover, multivariate analysis showed that decreased DGLA and increased delta-5 desaturase activity remained significant predictors of delirium. Conclusions: Low omega-6 PUFA levels and high delta-5 desaturase activity on admission were significantly associated with the development of delirium in the CICU, indicating that the evaluation of low omega-6 PUFA levels and related enzymes may identify patients at a high risk of developing delirium.

1. Introduction

Delirium frequently occurs in patients receiving intensive care. Approximately one-third of hospitalized individuals aged 70 years or older experience this condition [1]. Numerous risk factors have been linked to the onset of delirium, including advanced age, impaired ability to perform daily activities, pre-existing dementia, the administration of antipsychotic medications, use of feeding tubes, peripheral venous or urinary catheters, physical restraints, and nutritional deficiencies [2,3]. In particular, inadequate nutritional intake has been implicated in the early emergence of postoperative delirium among surgical patients [4,5]. Moreover, our prior research demonstrated that malnutrition contributes to the development of delirium in individuals with acute cardiovascular conditions admitted to a coronary intensive care unit (CICU) [6]. However, the pathophysiological mechanisms underlying delirium remain poorly understood [1]. Delirium has been linked to adverse clinical outcomes, including cognitive and functional decline, an increased likelihood of discharge to care facilities rather than returning home, and both short- and long-term mortality—especially among patients with acute cardiac conditions [2,7]. Therefore, early identification and prevention of delirium are essential for improving prognosis in this vulnerable population.
Essential fatty acids (EFAs) and their long-chain polyunsaturated derivatives (LCPs) play a fundamental role in human growth and health maintenance. Since humans lack the ability to produce EFAs and can only inefficiently convert them into LCPs, daily dietary intake of EFAs is essential [8,9]. The primary EFAs in the n-6 and n-3 families are linoleic acid (LA; 18:2n-6) and alpha-linolenic acid (ALA; 18:3n-3), respectively. These parent fatty acids undergo desaturation and elongation in the body, leading to the formation of longer-chain, more unsaturated LCPs. Among the metabolites of LA, dihomo-gamma-linolenic acid (DGLA; 20:3n-6) and arachidonic acid (AA; 20:4n-6) are particularly notable. These are classified as omega-6 polyunsaturated fatty acids (PUFAs) due to the location of their first double bond at the sixth carbon from the methyl end. On the other hand, eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), which are generated from ALA, belong to the omega-3 PUFA family, as their first double bond appears at the third carbon [10,11]. Omega-3 PUFAs are predominantly found in marine oils, such as fish oil, whereas omega-6 PUFAs are abundant in meats and in plant oils like sunflower, safflower, and corn oil [12].
In recent years, nutritional assessment has become an increasingly recognized component of cardiovascular disease management [13]. Of particular interest is the role of PUFAs in cardiovascular health, which has been the subject of extensive investigation [14,15,16,17,18]. In our earlier research, we found that reduced levels of omega-6 polyunsaturated fatty acids were significantly linked to increased long-term mortality across different nutritional statuses in patients with acute decompensated heart failure (ADHF) [19]. There is still a lack of evidence identifying which types of PUFAs may help reduce the incidence of delirium and improve prognosis in individuals with heart disease.
Accordingly, this study sought to investigate the relationship between the polyunsaturated fatty acid profile at the time of admission and the onset of delirium in patients presenting with acute cardiovascular conditions.

2. Materials and Methods

2.1. Study Design and Participants

This investigation was embedded within an ongoing prospective cohort study focusing on biomarkers in CICU-admitted patients. Although the hypothesis concerning PUFAs emerged retrospectively, all data were gathered in a systematic and prospective manner. We screened 783 consecutive patients who were admitted to the CICU of Juntendo University Hospital between January 2015 and December 2016. Among patients with multiple CICU admissions during the study period, only the first admission was included; subsequent admissions (n = 85) were excluded. An additional 36 patients were excluded due to incomplete delirium score assessments. Because of the difficulty in evaluating delirium, 9 patients who either required mechanical ventilation or exhibited profound impairments in consciousness were also excluded. Furthermore, 63 patients without PUFA measurements were excluded. As a result, 590 patients with both completed delirium assessments and PUFA level measurements were included in the final analysis. These patients were divided into two groups—delirium and non-delirium—to investigate the association between PUFA levels and the occurrence of delirium.
Delirium was identified based on an Intensive Care Delirium Screening Checklist (ICDSC) score of 4 or higher [20]. The evaluations were performed three times daily by independent nursing staff. To support the circadian rhythm, patients in the CICU were exposed to natural daylight during the day, and the lights were dimmed at night to simulate a normal day–night cycle. Additionally, to help orient patients to time and place, each room was equipped with a clock, and nurses routinely confirmed the date with patients each day. Bringing photographs of family members was also permitted.
All relevant data were collected from medical records at the time of hospital admission, including age, sex, body mass index (BMI), left ventricular ejection fraction (LVEF), comorbidity history (e.g., diabetes mellitus, dyslipidemia, hypertension, atrial fibrillation, dementia, cerebral infarction, and malignancy), reason for admission (e.g., ADHF, acute coronary syndrome (ACS), aortic dissection, pulmonary thromboembolism/deep vein thrombosis, ventricular tachycardia/ventricular fibrillation, and other causes), laboratory test results, and pre-admission medication use.
To ensure consistency and reproducibility, the definitions of key clinical conditions at the time of hospital admission used in this study are provided as follows: BMI was measured at the time of admission. LVEF was measured by transthoracic echocardiography upon admission. Diabetes mellitus was determined by either a documented diagnosis in the admission records, a hemoglobin A1c (HbA1c) level exceeding 6.5% as standardized by the National Glycohemoglobin Standardization Program, or the use of antidiabetic medications, including insulin. Dyslipidemia was identified through a recorded diagnosis at admission, abnormal lipid levels—specifically, triglycerides (TG) > 150 mg/dL, low-density lipoprotein cholesterol (LDL-C) > 140 mg/dL, or high-density lipoprotein cholesterol (HDL-C) < 40 mg/dL—or current use of lipid-lowering therapy. Hypertension was defined as a diagnosis noted at admission, systolic blood pressure greater than 140 mmHg and/or diastolic pressure over 90 mmHg, or ongoing treatment with antihypertensive drugs. Atrial fibrillation, dementia, prior cerebral infarction, and malignancy were confirmed based on documented admission diagnoses in the medical records.
The definitions of reasons for hospital admission were as follows: The diagnosis of ADHF was based on the criteria established by the Framingham study. [21]. ACS was characterized by the presence of unstable angina, non–ST-elevation myocardial infarction, or ST-elevation myocardial infarction [22]. Aortic diseases, pulmonary thromboembolism/deep vein thrombosis, ventricular tachycardia/ventricular fibrillation, and other conditions were defined based on the documented admission diagnoses in the medical records.
All subjects provided informed consent, and this study was approved by the Ethical Committee of Juntendo University Hospital.

2.2. Blood Sampling

Serum levels of PUFAs were assessed under fasting conditions within 24 h after hospital admission. Blood samples were withdrawn into ethylenediamine tetra acetic acid vacutainers and centrifuged at 2000 rpm at 4 °C for 20 min. Serum samples were stored at −80 °C until for PUFA concentration analysis. PUFAs, including DGLA, AA, EPA, and DHA, were measured using gas chromatography by SRL, Inc. (Tokyo, Japan), a certified clinical laboratory. All other laboratory tests were performed at the hospital’s central laboratory using standardized procedures. Plasma concentrations of total cholesterol (TC), TG, and HDL-C were determined using conventional enzymatic assays, while LDL-C was estimated via the Friedewald equation. Additional laboratory parameters, including albumin, HbA1c, C-reactive protein (CRP), creatinine, and N-terminal pro-brain natriuretic peptide (NT-proBNP), were measured according to standardized clinical protocols [23].

2.3. Statistical Analysis

Continuous data are presented as means with standard deviations, while categorical data are shown as percentages. Group comparisons were conducted using the Student’s t-test, the chi-square test, or Fisher’s exact test, as appropriate. The distribution of continuous variables was evaluated, and normality was assessed using the Shapiro–Wilk test. For variables that did not meet the assumption of normality, the Mann–Whitney U test was applied. To account for the risk of type I error due to multiple comparisons, Bonferroni correction was applied. A total of six predefined comparisons were made between the delirium and non-delirium groups, including four individual fatty acids (DGLA, AA, EPA, DHA) and two fatty acid ratios (AA/DGLA and EPA/AA). Simple linear regression was employed to assess relationships between pairs of continuous variables. To determine independent predictors of delirium in the CICU, multivariate logistic regression analysis was performed. Covariates were selected based on clinical relevance and previously established associations with the outcome. Variables showing significant associations in univariate analyses (p < 0.05) were considered for inclusion in the multivariate model, while avoiding multicollinearity. All statistical analyses were performed using JMP (version 17.0 for Macintosh, SAS Institute, Cary, NC, USA), and a two-tailed p value of <0.05 was considered statistically significant.

3. Results

3.1. Baseline Characteristics

A total of 590 patients with acute cardiovascular disease who were admitted to the CICU were included in this study. The average age of the participants was 70 years, with a standard deviation of 14 years. Among the enrolled patients, 400 (67.8%) were male, and all individuals were of Japanese ethnicity.
Delirium developed in 55 patients (9.3%). Age and percentage of men were significantly higher, and BMI was significantly lower in the delirium group. Comorbidities on admission, including atrial fibrillation and dementia, were significantly more common in the delirium group. Compared to the non-delirium group, the delirium group had a significantly higher incidence of ADHF and a significantly lower incidence of ACS as the reason for hospital admission. TC, LDL-C, HDL-C, and albumin levels were significantly lower in the delirium group. Serum creatinine, CRP, and NT-pro BNP levels were significantly higher in the delirium group. The use of antipsychotics was significantly higher in the delirium group, whereas there were no significant differences in the use of other medications between the two groups (Table 1). Additionally, the length of stay in the CICU was significantly longer in patients with delirium than in those without delirium (15.8 ± 19.0 vs. 6.4 ± 5.9 days, p < 0.001).

3.2. PUFA Levels and the Development of Delirium

As shown in Figure 1, DGLA levels were significantly lower in patients with delirium than in those without delirium (23.0 ± 10.2 vs. 31.4 ± 12.6 µg/mL, p < 0.001). In contrast, levels of AA (158.9 ± 60.8 vs. 168.7 ± 45.6 µg/mL, p = 0.053), EPA (50.1 ± 31.7 vs. 57.9 ± 38.8 µg/mL, p = 0.156), and DHA (120.9 ± 48.6 vs. 122.8 ± 43.7 µg/mL, p = 0.612) did not significantly differ between the two groups. Figure 2 shows that delta-5 desaturase activity estimated as AA/DGLA significantly increased in the delirium group than in the non-delirium group (7.4 ± 2.4 vs. 5.9 ± 2.0, p < 0.001). The EPA/AA ratio was not associated with the occurrence of delirium (0.34 ± 0.25 vs. 0.36 ± 0.26, p = 0.446). The p-values for DGLA and the AA/DGLA ratio were both below 0.001. After Bonferroni correction for multiple comparisons, these associations remained statistically significant (adjusted p < 0.006).

3.3. PUFA Levels, the ICDSC Score, and the Duration of Delirium

As shown in Table 2, the maximum delirium score showed weak but significant negative relationships with DGLA and AA, and positive relationships with delta-5 desaturase activity (DGLA: p < 0.001; AA: p = 0.002; AA/DGLA: p < 0.001). DGLA and AA levels were negatively associated with the duration of delirium (DGLA, p = 0.001; AA, p = 0.004). In addition, EPA and DHA levels tended to be negatively associated, and delta-5 desaturase activity (AA/DGLA) tended to be positively associated with the duration of delirium.

3.4. Multivariate Analysis

After controlling for potential confounders, both DGLA and delta-5 desaturase activity (AA/DGLA) were independent risk factors for onset of delirium in the CICU (Table 3). Model 1 was adjusted for age, sex, and BMI; Model 2 was adjusted for Model 1 and presence of ADHF and dementia; and Model 3 was adjusted for Model 2 and inflammation (CRP levels), renal dysfunction (creatinine levels), and malnutrition (albumin levels).

4. Discussion

This study revealed a significant association between reduced omega-6 PUFA levels at the time of admission and the occurrence of delirium in patients with acute cardiovascular disease admitted to the CICU. Specifically, lower levels of DGLA and elevated delta-5 desaturase activity (reflected by the AA/DGLA ratio) were independently linked to the presence of delirium. These findings suggest that diminished omega-6 PUFAs—particularly DGLA—may serve as potential markers for identifying patients at elevated risk for developing delirium. To our knowledge, this is the first investigation to demonstrate a relationship between low omega-6 PUFA levels and delirium onset.
The biological processes contributing to the development of delirium are not yet fully elucidated [1]. Nonetheless, growing evidence indicates that delirium arises from the complex interplay of multiple biological processes, ultimately disturbing large-scale neural networks and resulting in acute cognitive impairment. Proposed mechanisms underlying this condition include imbalances in neurotransmitter systems, systemic inflammation, physical stress, metabolic abnormalities, disturbances in electrolyte balance, and genetic predispositions [3]. However, the concept of a singular, unified mechanism—often referred to as the “final common pathway”—for delirium remains unresolved [3,24].
Several studies have investigated the relationship between PUFAs and cognitive impairments. One such study suggested that long-chain omega-3 PUFAs may enhance cerebral function by promoting vasodilation and improving blood flow through their effects on endothelial cells within the brain’s vascular system [25]. Another investigation found that a higher dietary omega-6 to omega-3 ratio was positively correlated with an increased risk of developing Alzheimer’s disease [26]. A recent study offered new insights into how a balanced ratio of plasma phospholipid omega-3 and omega-6 PUFAs may support memory function and maintain the integrity of white matter microstructure [27]. However, in a previous study, intravenous delivery of omega-3 fatty acids in critically ill patients with sepsis did not reduce the incidence of septic-associated delirium [28].
This study found that elevated delta-5 desaturase activity, potentially leading to decreased DGLA and increased AA levels, was linked to the onset of delirium. Delta-5 desaturase introduces a double bond at the fifth position from the carboxyl end of fatty acid chains. Through this enzymatic activity, it converts DGLA into AA and eicosatetraenoic acid into EPA, using these molecules as its respective substrates [29]. Recent studies have linked delta-5 desaturase activity to various health conditions, such as cardiovascular disease, diabetes, cancer, and neurological disorders [30,31,32,33]. A study suggested that gene expression of delta-5 desaturase influences cognitive function across diverse neural tissues and distinct cell populations [33]. However, how delta-5 desaturase activity influences brain function remains unclear, and further studies are warranted to clarify the mechanisms underlying these associations.
Growing evidence demonstrates the coronary artery disease (CAD) benefits of dietary omega-6 PUFAs [34]. Replacing saturated fatty acids (SFAs) with omega-6 PUFAs lowered the incidence of CAD events by 24% in a pooled analysis of six randomized controlled trials, an effect likely mediated by substantial lowering of LDL-C. Additionally, a substantial body of evidence from short-term controlled feeding trials has shown that omega-6 polyunsaturated fatty acids possess cholesterol-lowering effects independent of simply replacing saturated fats [35,36,37]. In our previous work, we found that reduced levels of omega-6 fatty acids were linked to unfavorable outcomes in patients with acute cardiovascular conditions and ADHF [19,23]. There is still controversy surrounding the mechanisms by which omega-6 PUFAs may contribute to cardiovascular disease through their potential role in delirium development. Therefore, future studies should focus on the associations between PUFAs and cardiovascular disease and cognitive function.
The 2013 guidelines on lifestyle management to reduce cardiovascular risk suggest the replacement of PUFAs with SFA [38]. Furthermore, the 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease recommends limiting trans fat intake due to its harmful effects on lipid profiles and lipoproteins, as well as its role in promoting endothelial dysfunction, insulin resistance, inflammation, and arrhythmias. These effects have also been linked to increased all-cause mortality in the REGARDS study [39,40]. However, there is no evidence to support that omega-6 PUFA supplementation improves the prognosis of patients with cardiovascular diseases. Further studies are required to establish dietary guidelines, particularly concerning the optimal fatty acid composition for patients with cardiovascular disease.
This study has several limitations. First, it was conducted at a single center with a relatively small sample size. Larger, multicenter studies are warranted to more accurately evaluate the relationship between various nutritional indicators, PUFA levels, and delirium onset in patients with cardiovascular disease. Second, we were unable to obtain detailed information on patients’ dietary habits and physical activity levels. As a result, we could not explore potential links between pre-admission lifestyle factors and PUFA status. Third, although the number of primary comparisons was limited and Bonferroni correction was applied, multiple statistical tests were conducted, which increases the risk of type I error—namely, observing statistically significant results by chance despite the absence of a true effect. Therefore, our findings should be interpreted with appropriate caution.

5. Conclusions

Low levels of omega-6 PUFAs, particularly DGLA, at the time of admission were significantly associated with the onset of delirium in patients with acute cardiovascular disease admitted to the CICU. These findings suggest that reduced omega-6 PUFA levels may serve as a potential marker for identifying patients at elevated risk of developing delirium. Further studies are needed to elucidate the biological pathways that link PUFA status to delirium. From a public health standpoint, attention is increasingly being directed toward the balance between omega-6 and omega-3 fatty acids. Consequently, identifying the determinants of this PUFA ratio is highly relevant for advancing cardiovascular health strategies. Ultimately, we aim to contribute to the development of practical dietary and clinical protocols that support better outcomes in patients with cardiovascular disease.

Author Contributions

T.M. (Tetsuro Miyazaki) and K.S. (Kazunori Shimada) acquired permission from the ethical committee. Data sampling was performed by T.M. (Tetsuro Miyazaki) and Y.S.-Y. with the help of M.S., S.O., T.A., T.S., K.T., M.H. and S.T. Furthermore, Y.S.-Y. and T.M. (Tetsuro Miyazaki) performed data analysis with the help of K.S. (Kazunori Shimada) and K.S. (Katsuhiko Sumiyoshi). The manuscript was drafted by Y.S.-Y., T.M. (Tetsuro Miyazaki), K.S. (Kazunori Shimada) and T.M. (Tohru Minamino). All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported, in part, by JSPS KAKENHI Grant Numbers JP15K00845, JP19K11774, and 22K11761.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Juntendo University Hospital (the protocol code: 871; the date of approval: 9 March 2012).

Informed Consent Statement

Informed consent was obtained from all subjects involved in this study.

Data Availability Statement

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Marcantonio, E.R. Delirium in Hospitalized Older Adults. N. Engl. J. Med. 2017, 377, 1456–1466. [Google Scholar] [CrossRef] [PubMed]
  2. Bellelli, G.; Morandi, A.; Di Santo, S.G.; Mazzone, A.; Cherubini, A.; Mossello, E.; Bo, M.; Bianchetti, A.; Rozzini, R.; Zanetti, E.; et al. “Delirium Day”: A nationwide point prevalence study of delirium in older hospitalized patients using an easy standardized diagnostic tool. BMC Med. 2016, 14, 106. [Google Scholar] [CrossRef] [PubMed]
  3. Inouye, S.K.; Westendorp, R.G.J.; Saczynski, J.S. Delirium in elderly people. Lancet 2014, 383, 911–922. [Google Scholar] [CrossRef]
  4. Ringaitiene, D.; Gineityte, D.; Vicka, V.; Zvirblis, T.; Sipylaite, J.; Irnius, A.; Ivaskevicius, J.; Kacergius, T. Impact of malnutrition on postoperative delirium development after on pump coronary artery bypass grafting. J. Cardiothorac. Surg. 2015, 10, 74. [Google Scholar] [CrossRef]
  5. Mazzola, P.; Ward, L.; Zazzetta, S.; Broggini, V.; Anzuini, A.; Valcarcel, B.; Brathwaite, J.S.; Pasinetti, G.M.; Bellelli, G.; Annoni, G. Association Between Preoperative Malnutrition and Postoperative Delirium After Hip Fracture Surgery in Older Adults. J. Am. Geriatr. Soc. 2017, 65, 1222–1228. [Google Scholar] [CrossRef]
  6. Sugita, Y.; Miyazaki, T.; Shimada, K.; Shimizu, M.; Kunimoto, M.; Ouchi, S.; Aikawa, T.; Kadoguchi, T.; Kawaguchi, Y.; Shiozawa, T.; et al. Correlation of Nutritional Indices on Admission to the Coronary Intensive Care Unit with the Development of Delirium. Nutrients 2018, 10, 1712. [Google Scholar] [CrossRef]
  7. Falsini, G.; Grotti, S.; Porto, I.; Toccafondi, G.; Fraticelli, A.; Angioli, P.; Ducci, K.; Liistro, F.; Pieroni, M.; Taddei, T.; et al. Long-term prognostic value of delirium in elderly patients with acute cardiac diseases admitted to two cardiac intensive care units: A prospective study (DELIRIUM CORDIS). Eur. Heart J. Acute Cardiovasc. Care 2017, 7, 661–670. [Google Scholar] [CrossRef]
  8. Hornstra, G. Essential fatty acids in mothers and their neonates. Am. J. Clin. Nutr. 2000, 71, 1262s–1269s. [Google Scholar] [CrossRef]
  9. Aaes-Jorgensen, E. Essential fatty acids. Physiol. Rev. 1961, 41, 1–51. [Google Scholar] [CrossRef]
  10. Russo, G.L. Dietary n-6 and n-3 polyunsaturated fatty acids: From biochemistry to clinical implications in cardiovascular prevention. Biochem. Pharmacol. 2009, 77, 937–946. [Google Scholar] [CrossRef]
  11. Salem, N., Jr.; Ward, G.R. Are omega 3 fatty acids essential nutrients for mammals? World Rev. Nutr. Diet. 1993, 72, 128–147. [Google Scholar] [CrossRef] [PubMed]
  12. Ghosh, S.; DeCoffe, D.; Brown, K.; Rajendiran, E.; Estaki, M.; Dai, C.; Yip, A.; Gibson, D.L. Fish oil attenuates omega-6 polyunsaturated fatty acid-induced dysbiosis and infectious colitis but impairs LPS dephosphorylation activity causing sepsis. PLoS ONE 2013, 8, e55468. [Google Scholar] [CrossRef] [PubMed]
  13. Mampuya, W.M. Cardiac rehabilitation past, present and future: An overview. Cardiovasc. Diagn. Ther. 2012, 2, 38–49. [Google Scholar] [CrossRef]
  14. Yokoyama, M.; Origasa, H.; Matsuzaki, M.; Matsuzawa, Y.; Saito, Y.; Ishikawa, Y.; Oikawa, S.; Sasaki, J.; Hishida, H.; Itakura, H.; et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007, 369, 1090–1098. [Google Scholar] [CrossRef]
  15. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet 1999, 354, 447–455. [Google Scholar]
  16. Marchioli, R.; Barzi, F.; Bomba, E.; Chieffo, C.; Di Gregorio, D.; Di Mascio, R.; Franzosi, M.G.; Geraci, E.; Levantesi, G.; Maggioni, A.P.; et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002, 105, 1897–1903. [Google Scholar] [CrossRef]
  17. Farvid, M.S.; Ding, M.; Pan, A.; Sun, Q.; Chiuve, S.E.; Steffen, L.M.; Willett, W.C.; Hu, F.B. Dietary linoleic acid and risk of coronary heart disease: A systematic review and meta-analysis of prospective cohort studies. Circulation 2014, 130, 1568–1578. [Google Scholar] [CrossRef]
  18. Petrone, A.B.; Weir, N.; Hanson, N.Q.; Glynn, R.; Tsai, M.Y.; Gaziano, J.M.; Djoussé, L. Omega-6 fatty acids and risk of heart failure in the Physicians’ Health Study. Am. J. Clin. Nutr. 2013, 97, 66–71. [Google Scholar] [CrossRef]
  19. Ouchi, S.; Miyazaki, T.; Shimada, K.; Sugita, Y.; Shimizu, M.; Murata, A.; Kato, T.; Aikawa, T.; Suda, S.; Shiozawa, T.; et al. Decreased circulating dihomo-gamma-linolenic acid levels are associated with total mortality in patients with acute cardiovascular disease and acute decompensated heart failure. Lipids Health Dis. 2017, 16, 150. [Google Scholar] [CrossRef]
  20. Sakaguchi, T.; Watanabe, M.; Kawasaki, C.; Kuroda, I.; Abe, H.; Date, M.; Ueda, Y.; Yasumura, Y.; Koretsune, Y. A novel scoring system to predict delirium and its relationship with the clinical course in patients with acute decompensated heart failure. J. Cardiol. 2017, 71, 564–569. [Google Scholar] [CrossRef]
  21. McKee, P.A.; Castelli, W.P.; McNamara, P.M.; Kannel, W.B. The natural history of congestive heart failure: The Framingham study. N. Engl. J. Med. 1971, 285, 1441–1446. [Google Scholar] [CrossRef] [PubMed]
  22. Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Chaitman, B.R.; Bax, J.J.; Morrow, D.A.; White, H.D.; Mickley, H.; Crea, F.; Van de Werf, F.; et al. Fourth universal definition of myocardial infarction (2018). Kardiol. Pol. 2018, 76, 1383–1415. [Google Scholar] [CrossRef] [PubMed]
  23. Ouchi, S.; Miyazaki, T.; Shimada, K.; Sugita, Y.; Shimizu, M.; Murata, A.; Kato, T.; Aikawa, T.; Suda, S.; Shiozawa, T.; et al. Low Docosahexaenoic Acid, Dihomo-Gamma-Linolenic Acid, and Arachidonic Acid Levels Associated with Long-Term Mortality in Patients with Acute Decompensated Heart Failure in Different Nutritional Statuses. Nutrients 2017, 9, 956. [Google Scholar] [CrossRef]
  24. Sanford, A.M.; Flaherty, J.H. Do nutrients play a role in delirium? Curr. Opin. Clin. Nutr. Metab. Care 2014, 17, 45–50. [Google Scholar] [CrossRef]
  25. Kuszewski, J.C.; Wong, R.H.X.; Howe, P.R.C. Effects of Long-Chain Omega-3 Polyunsaturated Fatty Acids on Endothelial Vasodilator Function and Cognition-Are They Interrelated? Nutrients 2017, 9, 487. [Google Scholar] [CrossRef]
  26. Loef, M.; Walach, H. The omega-6/omega-3 ratio and dementia or cognitive decline: A systematic review on human studies and biological evidence. J. Nutr. Gerontol. Geriatr. 2013, 32, 1–23. [Google Scholar] [CrossRef]
  27. Zamroziewicz, M.K.; Paul, E.J.; Zwilling, C.E.; Barbey, A.K. Predictors of Memory in Healthy Aging: Polyunsaturated Fatty Acid Balance and Fornix White Matter Integrity. Aging Dis. 2017, 8, 372–383. [Google Scholar] [CrossRef]
  28. Burkhart, C.S.; Dell-Kuster, S.; Siegemund, M.; Pargger, H.; Marsch, S.; Strebel, S.P.; Steiner, L.A. Effect of n-3 fatty acids on markers of brain injury and incidence of sepsis-associated delirium in septic patients. Acta Anaesthesiol. Scand. 2014, 58, 689–700. [Google Scholar] [CrossRef]
  29. Lee, J.M.; Lee, H.; Kang, S.; Park, W.J. Fatty Acid Desaturases, Polyunsaturated Fatty Acid Regulation, and Biotechnological Advances. Nutrients 2016, 8, 23. [Google Scholar] [CrossRef]
  30. Arai, K.; Koba, S.; Yokota, Y.; Tsunoda, F.; Tsujita, H.; Kondo, S.; Tsukamoto, S.; Shoji, M.; Shinke, T. Relationships of Fatty Acids, Delta-5 Desaturase Activity, and Lipid Profiles in Men with Acute Coronary Syndrome. J. Atheroscler. Thromb. 2020, 27, 1216–1229. [Google Scholar] [CrossRef]
  31. Tsurutani, Y.; Inoue, K.; Sugisawa, C.; Saito, J.; Omura, M.; Nishikawa, T. Increased Serum Dihomo-γ-linolenic Acid Levels Are Associated with Obesity, Body Fat Accumulation, and Insulin Resistance in Japanese Patients with Type 2 Diabetes. Intern. Med. 2018, 57, 2929–2935. [Google Scholar] [CrossRef] [PubMed]
  32. Pang, L.; Shah, H.; Xu, Y.; Qian, S. Delta-5-desaturase: A novel therapeutic target for cancer management. Transl. Oncol. 2021, 14, 101207. [Google Scholar] [CrossRef] [PubMed]
  33. Wu, X.; Jiang, L.; Qi, H.; Hu, C.; Jia, X.; Lin, H.; Wang, S.; Lin, L.; Zhang, Y.; Zheng, R.; et al. Brain tissue- and cell type-specific eQTL Mendelian randomization reveals efficacy of FADS1 and FADS2 on cognitive function. Transl. Psychiatry 2024, 14, 77. [Google Scholar] [CrossRef]
  34. Balk, E.M.; Lichtenstein, A.H. Omega-3 Fatty Acids and Cardiovascular Disease: Summary of the 2016 Agency of Healthcare Research and Quality Evidence Review. Nutrients 2017, 9, 865. [Google Scholar] [CrossRef]
  35. Drouin-Chartier, J.P.; Tremblay, A.J.; Lépine, M.C.; Lemelin, V.; Lamarche, B.; Couture, P. Substitution of dietary ω-6 polyunsaturated fatty acids for saturated fatty acids decreases LDL apolipoprotein B-100 production rate in men with dyslipidemia associated with insulin resistance: A randomized controlled trial. Am. J. Clin. Nutr. 2018, 107, 26–34. [Google Scholar] [CrossRef]
  36. Kris-Etherton, P.M.; Fleming, J.A. Emerging nutrition science on fatty acids and cardiovascular disease: Nutritionists’ perspectives. Adv. Nutr. 2015, 6, 326s–337s. [Google Scholar] [CrossRef]
  37. Hegsted, D.M.; Ausman, L.M.; Johnson, J.A.; Dallal, G.E. Dietary fat and serum lipids: An evaluation of the experimental data. Am. J. Clin. Nutr. 1993, 57, 875–883. [Google Scholar] [CrossRef]
  38. Eckel, R.H.; Jakicic, J.M.; Ard, J.D.; de Jesus, J.M.; Miller, N.H.; Hubbard, V.S.; Lee, I.M.; Lichtenstein, A.H.; Loria, C.M.; Millen, B.E.; et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. Circulation 2014, 129, S76–S99. [Google Scholar] [CrossRef]
  39. Arnett, D.K.; Blumenthal, R.S.; Albert, M.A.; Buroker, A.B.; Goldberger, Z.D.; Hahn, E.J.; Himmelfarb, C.D.; Khera, A.; Lloyd-Jones, D.; McEvoy, J.W.; et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019, 140, e596–e646. [Google Scholar] [CrossRef]
  40. Kiage, J.N.; Merrill, P.D.; Robinson, C.J.; Cao, Y.; Malik, T.A.; Hundley, B.C.; Lao, P.; Judd, S.E.; Cushman, M.; Howard, V.J.; et al. Intake of trans fat and all-cause mortality in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) cohort. Am. J. Clin. Nutr. 2013, 97, 1121–1128. [Google Scholar] [CrossRef]
Nutrients 17 01979 g001
Figure 1. PUFAs and development of delirium. A comparison of PUFA concentrations revealed that patients with delirium had markedly lower levels of DGLA than those without delirium. Conversely, no significant differences were found between the two groups in terms of AA, EPA, or DHA levels. Results are expressed as mean ± standard deviation.
Figure 1. PUFAs and development of delirium. A comparison of PUFA concentrations revealed that patients with delirium had markedly lower levels of DGLA than those without delirium. Conversely, no significant differences were found between the two groups in terms of AA, EPA, or DHA levels. Results are expressed as mean ± standard deviation.
Nutrients 17 01979 g001
Nutrients 17 01979 g002
Figure 2. Balance of PUFAs and development of delirium. The AA/DGLA ratio, which reflects delta-5 desaturase activity, was significantly higher in patients who developed delirium than in those who did not. In contrast, no significant relationship was observed between the EPA/AA ratio and the incidence of delirium. Results are expressed as mean ± standard deviation.
Figure 2. Balance of PUFAs and development of delirium. The AA/DGLA ratio, which reflects delta-5 desaturase activity, was significantly higher in patients who developed delirium than in those who did not. In contrast, no significant relationship was observed between the EPA/AA ratio and the incidence of delirium. Results are expressed as mean ± standard deviation.
Nutrients 17 01979 g002
Table 1. Baseline characteristics of the study participants on admission (n = 590).
Table 1. Baseline characteristics of the study participants on admission (n = 590).
Delirium Group
(n = 55)		Non-Delirium Group
(n = 535)		p
Age, years80.3 ± 10.969.0 ± 13.8<0.001
Male, n (%)28 (51)372 (70)0.01
Body mass index, kg/m222.4 ±3.923.7 ± 4.50.02
Left ventricular ejection fraction, %55 ± 1455 ± 160.70
Comorbidities on admission
Dementia, n (%)16 (29)11 (2)<0.001
Atrial fibrillation, n (%)15 (28)83 (16)0.03
Malignancy, n (%)11 (20)59 (11)0.05
Hypertension, n (%)35 (64)279 (52)0.10
Diabetes mellitus, n (%)23 (42)154 (29)0.12
Cerebral infarction, n (%)6 (11)42 (7.9)0.43
Reason of hospital admission
Acute decompensated heart failure, n (%)35 (64)204 (38)<0.001
Acute coronary syndrome, n (%)7 (13)185 (35)0.001
Aortic disease, n (%)4 (7.3)16 (3.0)0.10
VT/VF, n (%)1 (1.8)15 (2.8)1.00
PTE/DVT, n (%)2 (3.6)20 (3.7)1.00
Others, n (%)6 (11)95 (18)0.54
Laboratory data
Albumin, g/dL3.13 ± 0.573.47 ± 0.56<0.001
CRP, mg/dL4.3 ± 6.01.9 ± 3.5<0.001
NT-pro BNP, pg/mL14718 ± 226406202 ± 15499<0.001
Total cholesterol, mg/dL147.8 ± 50.5163.0 ± 40.40.002
Creatinine, mg/dL1.92 ± 2.221.44 ± 1.810.003
LDL-C, mg/dL87.6 ± 34.2100.7 ± 33.30.003
HDL-C, mg/dL39.1 ± 12.543.3 ± 13.80.02
Triglycerides, mg/dL86.0 ± 57.093.3 ± 52.70.11
HbA1c, %6.43 ± 2.066.16 ± 0.990.51
Medication
Antipsychotics, n (%)2 (3.7)2 (0.4)0.04
Anticoagulants, n (%)14 (26)89 (17)0.10
Nonbenzodiazepines, n (%)2 (3.7)6 (1.1)0.16
Antiplatelets, n (%)16 (29)194 (36)0.29
β-blockers, n (%)20 (36)169 (32)0.50
Calcium channel blockers, n (%)15 (27)168 (31)0.53
Insulin, n (%)4 (7)30 (6)0.55
Statin, n (%)16 (29)176 (33)0.57
Oral hypoglycemic agents, n (%)11 (20)93 (18)0.59
ACE-I/ARBs, n (%)20 (36)178 (33)0.64
Anti-depressants, n (%)0 (0)3 (0.6)1.0
Anxiolytic drugs, n (%)0 (0)8 (1.5)1.0
Benzodiazepines, n (%)1 (1.9)19 (3.6)1.0
Data are presented as means ± SD or number (percentage). VT, ventricular tachycardia; VF, ventricular fibrillation; PTE, pulmonary thromboembolism; DVT, deep vein thrombosis; CRP, C-reactive protein; NT-pro BNP, N-terminal pro brain natriuretic peptide; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HbA1c, hemoglobin A1c, national glycohemoglobin standardization program calculation; ACE-I, angiotensin-converting-enzyme inhibitor; ARBs, angiotensin II receptor blockers.
Table 2. PUFA levels and the ISDSC score, PUFA levels and the duration of delirium.
Table 2. PUFA levels and the ISDSC score, PUFA levels and the duration of delirium.
Maximum ISDSC ScoreDuration of Delirium
rprp
DGLA (mg/dL)−0.231<0.001−0.1340.001
AA (mg/dL)−0.1310.002−0.1200.004
EPA (mg/dL)−0.0640.120−0.0800.052
DHA (mg/dL)−0.0480.236−0.0790.055
EPA/AA−0.0010.976−0.0310.456
AA/DGLA0.168<0.0010.0690.093
The bold means statistically significant values. DGLA, dihomo-gamma-linolenic acid; AA, arachidonic acid; EPA, eicosapentaenoic acids; DHA, docosahexaenoic acid.
Table 3. Multivariate logistic regression analyses for the occurrence of delirium.
Table 3. Multivariate logistic regression analyses for the occurrence of delirium.
UnivariateModel 1Model 2Model 3
OR95%CIpOR95%CIpOR95%CIpOR95%CIp
DGLA, 1 increase0.920.90–0.96<0.0010.930.90–0.97<0.0010.940.90–0.970.0010.950.91–0.990.009
DGLA as a categorical variable
1st quartile1.00reference 1.00reference 1.00reference 1.00reference
2nd quartile0.300.14–0.620.0010.330.15–0.700.0040.300.13–0.690.0050.350.15–0.830.02
3rd quartile0.220.10–0.49<0.0010.230.10–0.55<0.0010.200.08–0.520.0010.260.09–0.700.008
4th quartile0.130.05–0.35<0.0010.200.07–0.570.0030.210.07–0.620.0050.220.06–0.790.02
AA/DGLA, 1 increase1.331.18–1.50<0.0011.291.14–1.47<0.0011.301.13–1.49<0.0011.281.11–1.48<0.001
AA/DGLA as a categorical variable
1st quartile1.00reference 1.00reference 1.00reference 1.00reference
2nd quartile2.280.77–6.730.141.620.53–4.950.401.780.56–5.700.332.200.62–7.800.22
3rd quartile2.520.87–7.360.091.510.50–4.590.461.270.39–4.080.691.320.36–4.780.67
4th quartile6.342.37–17.0<0.0013.901.40–10.90.0093.641.24–10.70.023.741.12–12.50.03
Model 1 was adjusted for age, sex, and BMI; Model 2 was adjusted for Model 1 and presence of ADHF and dementia; and Model 3 was adjusted for Model 2 and inflammation (C-reactive protein levels), renal dysfunction (creatinine levels), and malnutrition (albumin levels), OR, odds ratio; 95%CI, 95% confidence interval. The bold means statistically significant values. DGLA, dihomo-gamma-linolenic acid; AA, arachidonic acid.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sugita-Yamaguchi, Y.; Miyazaki, T.; Shimada, K.; Shimizu, M.; Ouchi, S.; Aikawa, T.; Shiozawa, T.; Takasu, K.; Hiki, M.; Takahashi, S.; et al. Association Between Low Omega-6 Polyunsaturated Fatty Acid Levels and the Development of Delirium in the Coronary Intensive Care Unit. Nutrients 2025, 17, 1979. https://doi.org/10.3390/nu17121979

AMA Style

Sugita-Yamaguchi Y, Miyazaki T, Shimada K, Shimizu M, Ouchi S, Aikawa T, Shiozawa T, Takasu K, Hiki M, Takahashi S, et al. Association Between Low Omega-6 Polyunsaturated Fatty Acid Levels and the Development of Delirium in the Coronary Intensive Care Unit. Nutrients. 2025; 17(12):1979. https://doi.org/10.3390/nu17121979

Chicago/Turabian Style

Sugita-Yamaguchi, Yurina, Tetsuro Miyazaki, Kazunori Shimada, Megumi Shimizu, Shohei Ouchi, Tatsuro Aikawa, Tomoyuki Shiozawa, Kiyoshi Takasu, Masaru Hiki, Shuhei Takahashi, and et al. 2025. "Association Between Low Omega-6 Polyunsaturated Fatty Acid Levels and the Development of Delirium in the Coronary Intensive Care Unit" Nutrients 17, no. 12: 1979. https://doi.org/10.3390/nu17121979

APA Style

Sugita-Yamaguchi, Y., Miyazaki, T., Shimada, K., Shimizu, M., Ouchi, S., Aikawa, T., Shiozawa, T., Takasu, K., Hiki, M., Takahashi, S., Sumiyoshi, K., & Minamino, T. (2025). Association Between Low Omega-6 Polyunsaturated Fatty Acid Levels and the Development of Delirium in the Coronary Intensive Care Unit. Nutrients, 17(12), 1979. https://doi.org/10.3390/nu17121979

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop